Home Companies Catalysts Deep Dives

Acute myeloid leukemia

AML · Oncology · 3 drugs · 4 indications

Aggressive blood cancer affecting myeloid cells.
Competitive Landscape (3 drugs)
DrugCompanyMechanismModalityRouteStage
XospataALPMYFLT3 inhibitorSmall moleculePOAPPROVED
VanflytaDSNKYFLT3 inhibitorSmall moleculePOAPPROVED
VenclextaABBV, ROG.SWBCL-2 inhibitorSmall moleculePOAPPROVED
Indications (4)
FLT3+ R/R AML
Xospata APPROVED
FLT3-ITD+ AML, 1L
Vanflyta APPROVED
FLT3-ITD+ AML, R/R
R/R AML
Venclexta APPROVED
Upcoming Catalysts
Venclexta - HR-MDS - FDA ApprovalREGULATORY
ABBV2026
Xospata - Commercial UpdatesCOMMERCIAL
ALPMY2026
Data from Supabase · Updated 2026-03-24